Literature DB >> 33578833

Physiological Biomarkers Assessed by Low-Tech Exercise Tests Predict Complications and Overall Survival in Patients Undergoing Pneumonectomy Due to Lung Cancer.

Tomasz Marjanski1, Damian Wnuk2, Robert Dziedzic1, Marcin Ostrowski1, Wioletta Sawicka3, Ewa Marjanska4, Witold Rzyman1.   

Abstract

Due to its debilitating character pneumonectomy this is last-resort procedure. Preoperative results of the 6-min walking test (6MWT) help to identify high risk of postoperative complications and increased mortality in patients undergoing lobectomy for lung cancer. The aim of the study was to validate the value of 500 m in 6MWT as an indicator, which differentiates risk of complications in patients undergoing pneumonectomy. 125 patients who underwent pneumonectomy at Thoracic Surgery Department between 2009 and 2018. On the day preceding the surgery, patients underwent 6MWT. The patients were in median age of 63 years. The cut-off value of 500 m identified patients with increased 90-day mortality [17.9% vs. 3.5%, odds ratio (OR) 6.271, 95% confidence interval (CI) 1.528-25.739], first-year mortality (30.7% vs. 11.6%, OR 3.378, 95%CI 1.310-8.709), and overall survival (p = 0.02). Patients who covered a distance ≤ 500 m had an increased risk of atrial fibrillation (35.9% vs. 16.3%, OR 2.880, 95%CI 1.207-6.870) and cardiac complications (38.4% vs. 19.8%, OR 2.537, 95%CI 1.100-5.849). Patients unable to reach 500 m in 6MWT are in a high risk of postoperative death after pneumonectomy, what may be a result of increased frequency of postoperative cardiac complications. Poor result of 6MWT is a predictor of worse overall survival.

Entities:  

Keywords:  6-min walking test; complications; lung cancer; overall survival; pneumonectomy

Year:  2021        PMID: 33578833      PMCID: PMC7916610          DOI: 10.3390/cancers13040735

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  31 in total

1.  Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection.

Authors:  D A Holden; T W Rice; K Stelmach; D P Meeker
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

2.  Sleeve lobectomy may provide better outcomes than pneumonectomy for non-small cell lung cancer. A decade in a nationwide study.

Authors:  Pierre-Benoit Pagès; Pierre Mordant; Stéphane Renaud; Laurent Brouchet; Pascal-Alexandre Thomas; Marcel Dahan; Alain Bernard
Journal:  J Thorac Cardiovasc Surg       Date:  2016-10-13       Impact factor: 5.209

3.  Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer.

Authors:  Cecilia Pompili; Michele Salati; Majed Refai; Rossana Berardi; Azzurra Onofri; Paola Mazzanti; Alessandro Brunelli
Journal:  Eur J Cardiothorac Surg       Date:  2012-10-22       Impact factor: 4.191

4.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

5.  Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality.

Authors:  R J Pierce; J M Copland; K Sharpe; C E Barter
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

6.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

7.  ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.

Authors:  Filippo G Dall'Olio; Ilaria Maggio; Maria Massucci; Veronica Mollica; Benedetta Fragomeno; Andrea Ardizzoni
Journal:  Lung Cancer       Date:  2020-05-06       Impact factor: 5.705

8.  Result of the 6-min walk test is an independent prognostic factor of surgically treated non-small-cell lung cancer.

Authors:  Tomasz Marjanski; Michal Badocha; Damian Wnuk; Robert Dziedzic; Marcin Ostrowski; Wioletta Sawicka; Witold Rzyman
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-03-01

9.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.

Authors:  Brian L Graham; Irene Steenbruggen; Martin R Miller; Igor Z Barjaktarevic; Brendan G Cooper; Graham L Hall; Teal S Hallstrand; David A Kaminsky; Kevin McCarthy; Meredith C McCormack; Cristine E Oropez; Margaret Rosenfeld; Sanja Stanojevic; Maureen P Swanney; Bruce R Thompson
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

View more
  1 in total

1.  Diagnostic and Predictive Biomarkers in Lung Cancer.

Authors:  Caterina Fumagalli; Massimo Barberis
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.